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Insulin receptor tyrosine kinase
Insulin receptor substrate-1
Glucose uptake
Cell proliferation and survivalHere, we demonstrate that insulin receptor (IR) tyrosine kinase catalyzes Tyr-19 and Tyr-27 phosphorylation of
caveolin-2 (cav-2), leading to stimulation of signaling proteins downstreamof IR, and that the catalysis is depen-
dent on fatty acylation status of cav-2, promoting its interaction with IR. Cav-2 is myristoylated at Gly-2 and
palmitoylated at Cys-109, Cys-122, and Cys-145. The fatty acylation deﬁcient mutants are unable to localize in
the plasma membrane and not phosphorylated by IR tyrosine kinase. IR interacts with the C-terminal domain
of cav-2 containing the cysteines for palmitoylation. IR mutants, Y999F and K1057A, but not W1220S, fail inter-
action with cav-2. Insulin receptor substrate-1 (IRS-1) is recruited to interact with the IR-catalyzed phospho-
tyrosine cav-2, which facilitates IRS-1 association with and activation by IR to initiate IRS-1-mediated down-
stream signaling. Cav-2 fatty acylation and tyrosine phosphorylation are necessary for the IRS-1-dependent
PI3K-Akt and ERK activations responsible for glucose uptake and cell survival and proliferation. In conclusion,
fatty acylated cav-2 is a new substrate of IR tyrosine kinase, and the fatty acylation and phosphorylation of
cav-2 present novel mechanisms by which insulin signaling is activated.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Insulin receptor (IR) signaling pathways regulating metabolic and
mitogenic functions have been well documented [1]. IR signaling di-
verges into different pathways by activating multiple substrates.
Caveolins, lipid rafts-associated integral membrane proteins, are re-
quired for caveolar biogenesis and caveolin-1 (cav-1) in caveolae is
known to regulate IR signaling pathway [2,3]. IR was reported to phos-
phorylate cav-1 at Tyr-14 via binding of scaffolding domain of cav-1
(residues 82-101) to a speciﬁcmotif (residues 1220-1227;WSFGVVLW)
[2,4] within kinase domain of IR [2,5,6]. Caveolin-3 (cav-3) was also
reported to associate directly with IR and act as an enhancer of insulin
signaling in skeletal muscle [3,7]. However, recent structural and bioin-
formatic analyses argue against such direct physical interactions [8,9].
In a series of investigations, we have demonstrated that caveolin-2
(cav-2) interacts with IR and is phosphorylated at Tyr-19 and Tyr-27Cav-1, caveolin-1; IRS-1, insulin
M, plasma membrane; Hirc-B,
-BP, 2-bromopalmitate; MβCD,




82 55 759 9363.in response to insulin, and that the phospho-tyrosine cav-2 functions
as a mitogenic activator for insulin signaling in ﬁbroblasts [10–15]. Re-
cently, we have shown various intracellular distribution of cav-2 [15,
16] and demonstrated that cav-2 forms homooligomeric cav-2
noncaveolar microdomain in the plasma membrane (PM), in which
cav-2 facilitates IR recruiting and regulates activation of insulin signal-
ing cascade by direct interaction with IR [16]. However, the underlying
molecular mechanisms of their association and the consequent activa-
tion of downstream signaling have not been thoroughly investigated.
Fatty acylation of proteins is involved in the regulation of numerous
cellular processes including membrane targeting and subcellular traf-
ﬁcking of protein, vesicular biogenesis, receptor signaling, and protein
stability [17]. Multiple studies have described that both myristoylation
and palmitoylation of proteins play a role in their localization to lipid
rafts. Many signaling proteins residing inner side of the PM such as
Lck, Fyn, and ﬂotillins are both myristoylated and palmitoylated and
the fatty acylation mediates their raft membrane association in a
regulated fashion [18–20]. Cav-1 was shown to be palmitoylated at
Cys-133, Cys-143, and Cys-156. The palmitoylation was not required
for its localization to caveolae [21] and c-Src-mediated Tyr-14 phos-
phorylation of cav-1 was dependent on the palmitoylation at Cys-156
[22]. Cav-2 has putative cysteine residues at the C-terminal domain
and a glycine residue at the N-terminus, but actual palmitoylation on
the cysteine residues and myristoylation of the glycine are not demon-
strated. Thus, the functional consequence of fatty acylation of cav-2 is
not known.
1023H. Kwon et al. / Biochimica et Biophysica Acta 1853 (2015) 1022–1034Data are presented to show that (i) cav-2 is myristoylated at Gly-2
and palmitoylated at Cys-109, Cys-122, and Cys-145; (ii) the fatty acyl-
ation is indispensable for the PM localization of cav-2 to interactwith IR;
(iii) IR catalyzes Tyr-19 and Tyr-27 phosphorylation of the fatty acylated
cav-2; and (iv) IRS-1 binding to the phospho-tyrosine cav-2 facilitates
IRS-1 association with and tyrosine phosphorylation by IR for IRS-1-
directed metabolic and mitogenic insulin signaling activation.
2. Materials and methods
2.1. Materials
Antibodies and reagents used were purchased as follows: anti-cav-2
(BD 610685), anti-cav-1 (BD 610406), anti-phospho-tyrosine (PY20)
(BD 610000), anti-ERK (BD 610124), anti-IRS-1 (BD 611395),
and anti-E-cadherin (BD 610182) antibodies fromBD Transduction Lab-
oratories; anti-IR (sc-711), anti-pY1162/1163-IR (sc-25103), anti-GFP
(sc-9096 AC), anti- maltose binding protein (MBP) (sc-73416), anti-
α-tubulin (sc-5286), anti-calnexin (sc-11397), anti-Shc (sc-967), anti-
p85α (sc-423), and anti-F-actin (sc-1616) antibodies and imatinib-
mesylate (sc-202180) from Santa Cruz Biotechnology; anti-pT202/
204-ERK (#9101) and anti-pS473-Akt (#9271) antibodies from Cell
Signaling; anti-pY19-cav-2 (ab3417) and anti-phospho-serine (PS)
(ab17465) antibodies from Abcam; anti-pY418-Src (44660G) antibody
from Invitrogen; anti-FLAG® M2 (F 1804), FITC-conjugated anti-
mouse (F 0257), anti-rabbit (A 6154) and anti-mouse IgG-peroxidase/
HRP conjugate (A 4416) antibodies, and 2-bromopalmitate (2-BP)
(21064), methyl-β-cyclodextrin (MβCD) (C4555), and cycloheximide
(CHX) (C7698) from Sigma-Aldrich; PP2 (529573) from Calbiochem;
human insulin from Eli Lilly; [9,10-3H]Palmitic acid (30-60ci/mmol),
[9,10-3H]Myristic acid (10-60ci/mmol), and [γ-32P]ATP (6000ci/mmol)
from PerkinElmer Life Sciences.
2.2. Cell culture
Human insulin receptor-overexpressed rat 1 ﬁbroblast (Hirc-B) cells
[10,23] and cav-2 short-hairpin RNA (shRNA) stable Hirc-B cells
established as described [16] were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) containing 5 mM D-glucose supplemented
with 10% (v/v) fetal bovine serum (FBS) (Sigma), 100 nMmethotrexate
(Sigma), and 0.5% gentamycin (Gibco/BRL) in a 5% CO2 incubator
at 37 °C. HEK293T and Rat-1 cells were grown in DMEM containing
5 mM D-glucose supplemented with 10% (v/v) FBS and 0.5%
penicillin/streptomycin (Sigma) in a 5% CO2 incubator at 37 °C. 3T3L1
preadipocytes were grown in DMEM containing 25 mMD-glucose sup-
plemented with 10% calf serum (Gibco/BRL). Conﬂuent 3 T3-L1
preadipocytes were induced to differentiate into adipocytes as de-
scribed [24].
2.3. Plasmid constructs, mutagenesis and transfection
A full-length cav-2 cDNA was subcloned into pcDNA3 vector
(Invitrogen) [11]. Constructs encoding wild type (WT) cav-2 and point
mutants including G2A, C109A, C122A, C145A, C109/122A, C122/145A,
C109/145A, C109/122/145A (3CA), Y19A, Y27A, Y19/27A, and Y19/27E
were generated by PCR mutagenesis using mutated oligonucleotides.
Cav-2 domain truncation mutants including Δ1-13, Δ1-46, Δ1-70,
Δ47-86 and Δ120-162 were generated by using the cav-2-GFP (WT,
residues 1-162) as template via EZchange site-directed mutagenesis
kit (Enzynomics, Daejeon, Korea). The resulting entry vectors of WT
and mutants were converted into self-constructed FLAG tagging desti-
nation expression vector (pDS_FLAG-XB vector), GFP tagging destina-
tion expression vector (pEGFP-N1 vector, Clontech Laboratories), or
MBP tagging destination expression vector (pMGWA vector). IR
(NM_10051.1) plasmid (Gateway PLUS shuttle clone for INSR, GC-
Y2826-CF)was obtained fromGenecopoeia. For construction of a vectorexpressing FLAG-tagged IR, IR wasmoved into the pDS_FLAG-XB vector
using GatewayTM Technology (Invitrogen). A construct encoding Y999F,
W1220S, and K1057A mutants were generated by using the FLAG-IR
(WT) as template via EZchange site-directed mutagenesis kit. All ex-
pression vectors were veriﬁed by sequencing. The pECFP-Golgi and
pECFP-endoplasmic reticulum (ER) plasmids were obtained from
Clontech Laboratories. For transient expression of the plasmid con-
structs, HEK293T cells were transfected using a modiﬁed calcium phos-
phate precipitation protocol as described [10,14]. 3 T3-L1 adipocytes
were transfected by electroporation as described [25,26].
2.4. Silencing of IRS-1, cav-1 and cav-2 by RNA interference
Small interfering RNA (siRNA) targets of IRS-1 and cav-1 were pur-
chased from Bioneer Corp. (Daejon, Korea) and cav-2 and scramble con-
trol from Dharmacon. The siRNA oligonucleotides were synthesized to
the following target sequences: IRS-1; sense (5´-CGGUAUCGUUUCGC
AUGGA-3´) and anti-sense (5´-UCCAUGCGAAACGAUACCG-3´), cav-1;
sense (5´-CAGUUGUACCAUGCAUUAA-3´) and anti-sense (5´-UUAAUG
CAUGGUACAACUG-3´), cav-2; sense (5´-GUAAAGACCUGCCUAAUG
GUU-3´) and anti-sense (5´-PCCAUUAGGCAGGUCUUUACUU-3´), scram-
ble control; 5´-GGAAAGACUGUUCCAAAAA-3´. Transfection of the siRNA
duplexes was carried out using DharmaFECT Transfection Reagents
(Dharmacon) for 48 h.
2.5. Biochemical methods
Immunoblotting, immunoprecipitation (IP), densitometry, and
quantiﬁcation of cholesterol were performed as described [15,16].
2.6. In vitro kinase assay
Hirc-B cells were treated with or without 100 nM insulin for 10min
and lysed with IP buffer (1% Triton X-100, 150 mM NaCl, 10 mM
Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid
(EGTA) (pH 8.0), 0.2 mM sodium ortho-vanadate, 0.2 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 0.5% Nonidet P-40, and 60 mM
n-octylglucoside). Cell lysates were immunoprecipitated with anti-IR
antibody and the immunoprecipitateswerewashed two times in kinase
assay buffer (20 mM Hepes, pH 7.6, 20 mM MgCl2, 20 mM
β-glycerophosphate, 1 mM dithiothreitol, 10 μM ATP, 1 mM EDTA,
1 mM sodium ortho-vanadate, and 0.4 mM PMSF). The kinase assay
was conducted at 30 °C for 30 min in kinase assay buffer containing
5 μCi of [γ-32P]ATP and 20 μg of MBP-cav-2 (WT), MBP-Y19A, MBP-
Y27A, or MBP-Y19/27A. The reaction products were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred onto
polyvinylidene diﬂuoride (PVDF) membrane for autoradiography or
immunoblot analysis.
2.7. In vitro binding assay
HEK293T cells were transfected with FLAG vector, FLAG-IR,
FLAG-Y999F, FLAG-W1220S, or FLAG-K1057A for 48 h followed by incu-
bation with 100 nM insulin for 10 min and lysed with IP buffer. Cell ly-
sates (1 mg proteins) were incubated with puriﬁed MBP-cav-2, MBP-
Δ1-13, MBP-Δ1-46, MBP-Δ1-70, MBP-Δ47-86, or MBP-Δ120-162
(100 μg) prebound to amylose resin at 4 °C for 4 h. Amylose resins
were washed four times with IP buffer. Bound proteins were analyzed
by immunoblotting.
2.8. Metabolic labeling
Hirc-B and cav-2-transfected HEK293T cells were washed with
phosphate-buffered saline (PBS) and incubated in the DMEM contain-
ing 10 mg/ml fatty acid-free bovine serum albumin (BSA) for 1 h at
37 °C before incubation with 0.5 mCi/ml [9,10-3H]Palmitic acid or
1024 H. Kwon et al. / Biochimica et Biophysica Acta 1853 (2015) 1022–10340.4 mCi/ml [9,10-3H]Myristic acid for 4 h. The cells were lysed with IP
buffer and immunoprecipitated with anti-cav-2, anti-FLAG, or anti-
GFP antibodies. Following extensive washing captured proteins were
eluted, separated by SDS-PAGE, transferred to PVDFmembrane, and ex-
posed to light sensitive ﬁlm at -80 °C using a KODAK Biomax transcreen
LE (Sigma-Aldrich). The samemembranewas reprobedwith anti-cav-2,
anti-GFP or anti-FLAG antibodies.
2.9. Fatty acyl biotin exchange
Puriﬁcation of palmitoylated proteins by the fatty acyl biotin ex-
change (FAE) was performed as described [27]. Brieﬂy, cells were
lysed with buffer A (1% SDS in PBS containing 0.2 mM PMSF, 1 μg/μl
aprotinin, and 1 μg/μl leupeptin) and free cysteines alkylated by over-
night incubation at 4 °C with 25 mg/ml N-ethylmaleimide (NEM). Ex-
cess soluble NEM was removed by chloroform/methanol precipitation.
Protein pellets were resolubilized in buffer A, and the samples were di-
vided into two; half was treated with 200mMhydroxylamine (pH 7.4),
and half was treated with 200 mM Tris (pH 7.4). Lysates were treated
with 1 mM pyridyldithiol-activated cysteine-reactive biotinylation re-
agent N-[6-(Biotinamido)hexyl]-3´-(2´-pyridyldithio)-propionamide
for 1 h in the dark at room temperature and excess biotinylation reagent
was removed by chloroform/methanol precipitation. Protein pellets
were resolubilized in buffer B (1% Triton X-100 and 0.2% SDS in PBS con-
taining 0.2mMPMSF, 1 μg/μl aprotinin, and 1 μg/μl leupeptin). The sam-
ples were puriﬁed using NeutrAvidin-Agarose resin beads (Thermo
scientiﬁc) overnight at 4 °C. Beads were washed four times with buffer
B and biotinylated proteins were eluted in 5× SDS-PAGE sample buffer.
The biotinylated proteins were then resolved, separated by SDS-PAGE,
and subjected to immunoblot analysis.
2.10. Confocal microscopy
HEK293T cells were co-transfected with cav-2-GFP, G2A-GFP, 3CA-
GFP, C122/145A-GFP, C109/145A-GFP, or C109/122A-GFP and pECFP-
Golgi or pECFP-ER, or with cav-2-mCherry and IR-GFP for 48 h. The
cells were ﬁxed with 3.7% paraformaldehyde in PBS for 20 min and
rinsed with PBS. Fluorescent images were obtained using an Olympus
Fluoview 1000 confocal microscope attached to IX-81 inverted micro-
scope equipped with PlanApo 100×/1.35 oil immersion objective lens
(Olympus). GFP and CFP signals were excited using an Argon laser at
488 and 434 nm, respectively, and mCherry signal using a He-Ne laser
at 543 nm. FV10-ASW software (Olympus) was used to merge the im-
ages from GFP and CFP or mCherry. White lines drawn in the merge
panels were converted to plot proﬁles using the Line Proﬁle Tool of
Image-ProPlus 6.1 as described [14,15].
2.11. Cell proliferation and viability assay
3T3L1 preadipocytes or adipocytes (2 × 104) were plated in 96-well
plates and transfectedwith FLAG vector, FLAG-cav-2 (WT), or FLAG-3CA
for 24 h. The cells were pretreatedwith orwithout 10mMMβCD for 2 h
followed by incubation with 100 nM insulin for 72 h. 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (M5655,
Sigma-Aldrich) stock solution was added to each well at a ﬁnal concen-
tration of 0.5 mg/ml and incubated at 37 °C for 4 h, followed by lysis
with 100 μl of dimethyl sulfoxide (DMSO) (BioShop) to solubilize the
ﬁnal product of MTT metabolism, the formazan precipitate. After
30 min incubation at 37 °C, the optical density at 540 nm was deter-
mined using a microplate reader (Model 550, BioRad Laboratories).
2.12. Glucose uptake assay
Glucose uptake assay was performed using 2-deoxy-2-[(7-nitro-
2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG), a ﬂuorescent
glucose analog as described [28–30]. The 2-NBDG uptakewasmeasuredby using aGlucoseUptake Cell-basedAssay Kit (600470, CaymanChem-
ical Company) according to the manufacturer’s protocols. 3T3L1
preadipocytes (1 × 104) were seeded in 96-well plates and differentiat-
ed into adipocytes. The adipocytes were transfected with FLAG vector,
FLAG-cav-2 (WT), or FLAG-3CA for 48 h and pretreated with or without
10 mMMβCD for 2 h, or co-transfected with scramble control or cav-1
siRNA and FLAG vector, FLAG-cav-2 (WT), or FLAG-3CA for 48 h follow-
ed by incubationwith orwithout 100nM insulin for 10min. Uptakewas
then initiated by addition of 2-NBDG (150 μg/ml). After 10min of incu-
bation, the adipocytes were washed and the amount of 2-NBDG was
measured at excitation/emission 485/535 nm using amicroplate reader
(Model 550, BioRad Laboratories).
2.13. Statistical analysis
Data are expressed as mean ± S.E. and analyzed in Graphpad Prism
5.0 version. Statistical analysis of more than two groups was performed
by two-wayANOVA followed by Bonferroni post hoc test. Analysis com-
paring two groups was carried out using an unpaired Student’s t test. p
values b0.05 were considered statistically signiﬁcant.
3. Results
3.1. IR tyrosine kinase catalyzes phosphorylation of cav-2 at Tyr-19
and Tyr-27
Having shown that cav-2 interacts with IR and is phosphorylated at
Tyr-19 and Tyr-27 in response to insulin [11–13,16], it was important to
ﬁnd out whether the phosphorylation is catalyzed by IR tyrosine kinase
and to conﬁrm the direct and speciﬁc binding between cav-2 and IR.We
carried out in vitro kinase assay using MBP fusions of WT cav-2 and
Y19A, Y27A, and Y19/27A mutants as substrates for IR tyrosine kinase
(Fig. 1A). As compared with WT cav-2, 32P incorporation to Y19A and
Y27A mutants was decreased by 57.4 and 63.7%, respectively. Simulta-
neous mutation of both tyrosines (Y19/27A) abolished 32P incorpora-
tion, demonstrating that IR catalyzes the phosphorylation of cav-2 at
Tyr-19 and Tyr-27 (Fig. 1A). Tyrosine kinase activity of IR in response
to insulin was assessed by the IR phosphorylation at Tyr-1162/1163.
Since cav-2 was reported to be phosphorylated at Tyr-19 and Tyr-27
in c-Src-overexpressed ﬁbroblasts [31,32], Src-mediated phosphoryla-
tion was examined by using PP2, a selective inhibitor for Src-family ki-
nases. PP2 treatment inhibited Akt activation but did not affect
insulin-induced phosphorylation of cav-2 at Tyr-19 (Fig. 1B, a, lanes 2
vs. 4), suggesting that cav-2 is not a downstream effector for the c-Src
kinase-mediated insulin signaling axis. Since c-Abl kinase was reported
to phosphorylate cav-1 at Tyr-14 [33,34], we tested c-Abl kinase-
mediated phosphorylation of cav-2 by using imatinib-mesylate, a c-
Abl kinase inhibitor. Imatinib-mesylate treatment inhibited Akt activa-
tion (Fig. 1B, b, lanes 2 vs. 4) but did not affect the phosphorylation of
cav-2 at Tyr-19 with or without insulin stimulation (Fig. 1B, b, lanes 1
vs. 3 and 2 vs. 4). These data show that cav-2 is directly phosphorylated
by IR tyrosine kinase in response to insulin.
3.2. Cav-2 binds to the NPEY motif of IR
To identify the speciﬁc bindingmotifs of IR and cav-2 responsible for
their interaction in response to insulin, we mutated Tyr-999 within the
NPEY motif in the juxtamembrane domain of IR, which was important
for IR interaction with IRS-1 and Shc [35], to phenylalanine (Y999F mu-
tant) and Trp-1220 within the reported cav-1 binding motif (residues
1220-1227;WSFGVVLW) [2,4] in tyrosine kinase domain of IR to serine
(W1220Smutant). We also generated K1057Amutant, which is known
to abolish IR kinase activity and interaction with IR substrates by
disrupting the canonical ATP binding site [36]. IR mutant W1220S
interactedwith cav-2 but Y999F andK1057A did not (Fig. 1C, a). This re-
sult was further conﬁrmed by in vitro binding assay (Fig. 1C, b). In
Fig. 1. IR catalyzes phosphorylation of cav-2 at Tyr-19 and Tyr-27 via a speciﬁc interaction between the NPEYmotif of IR and the C-terminal domain of cav-2. (A) Hirc-B cells were treated
with orwithout 100 nM insulin for 10min.Whole cell lysates (WCL)were immunoprecipitatedwith anti-IR antibody and subjected to in vitro kinase assay using puriﬁedMBP-cav-2,MBP-
Y19A, MBP-Y27A or MBP-Y19/27A as a substrate. (B) Hirc-B cells were treated with or without 10 μM PP2 for 30 min (a) or 100 μM imatinib-mesylate for 1 h (b) followed by incubation
with orwithout 100 nM insulin for 10min.WCLwere subjected to immunoblot analysiswith antibodies against pY19-cav-2, pY1162/1163-IR, pS473-Akt, pT202/204-ERK, pY418-Src, and
actin. (C) (a) HEK293T cells were co-transfected with cav-2-GFP and FLAG vector, FLAG-IR, FLAG-Y999F, FLAG-W1220S, or FLAG-K1057A followed by incubation with 100 nM insulin for
10 min. WCL were immunoprecipitated with anti-FLAG antibody and subjected to immunoblot analysis with antibodies against GFP and FLAG. (b) HEK293T cells were transfected with
FLAG vector, FLAG-IR, FLAG-Y999F, FLAG-W1220S, or FLAG-K1057A followed by incubation with 100 nM insulin for 10 min. WCL were subjected to in vitro binding assay using puriﬁed
MBP-cav-2. (D) HEK293T cells were transfected with FLAG-IR followed by incubation with 100 nM insulin for 10 min. WCL were subjected to in vitro binding assay using puriﬁed MBP
vector, MBP-cav-2, MBP-Δ1-13, MBP-Δ1-46, MBP-Δ1-70, MBP-Δ47-86, or MBP-Δ120-162.
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ﬁnd out its IR-binding region. IR interacted with cav-2 mutants except
Δ120-162 mutant (Fig. 1D). Unlike cav-1 and cav-3 which are reported
to associate with IR thru their scaffolding domains, Δ1-70 and Δ47-86
mutants truncated on the scaffolding domain (residues 67-86)
interacted with IR but Δ120-162 mutant containing the intact scaffold-
ing domain did not (Fig. 1D). These data show that the C-terminal do-
main of cav-2 associates with the NPEY motif of insulin-activated IR.
3.3. Phospho-tyrosine cav-2 mediates IR-IRS-1-directed signaling
activation in response to insulin
To explore if cav-2 interferes IRS-1 binding to IR or vice versa, effects
of cav-2 shRNA and IRS-1 siRNAon their IR association and downstream
IR signaling activation were examined. In control cells, IRS-1 was
coimmunoprecipitatedwith pY19-cav-2 and pY1162/1163-IR and tyro-
sine phosphorylated in response to insulin (Fig. 2A, a, lanes 1 vs. 2). In
cav-2 shRNA stable cells, however, IRS-1 association with pY1162/
1163-IR and tyrosine phosphorylation were abrogated (Fig. 2A, a,
lanes 2 vs. 4). And retardation in phosphoinositide 3-kinase (PI3K) in-
teractionwith IRS-1 and decrease in PI3K activation in response to insu-
lin were detected with attenuation in downstream Akt and ERK
activations as compared to control cells (Fig. 2A, b, lanes 2 vs. 4 and
Fig. 2A, c). Shc did not interact with cav-2 and insulin-induced Shc asso-
ciation with IRwas unaffected by cav-2 depletion (Fig. 2B). Depletion of
IRS-1,which caused inhibition of Akt andERK activations (Fig. 2C, a), did
not affect insulin-induced pY19-cav-2 associationwith pY1162/1163-IR
(Fig. 2C, b). To verify the requirement of cav-2 tyrosine phosphorylation
catalyzed by IR for IRS-1 association with IR, their interaction inresponse to insulin was examined in the cav-2 tyrosine deﬁcient
mutants-expressed cells. Insulin-induced association between IR and
IRS-1 was signiﬁcantly decreased in Y19/27A mutant-expressed cells
as compared to the level of their association in WT cav-2-expressed
cells (Fig. 2D, lanes 4 vs. 6). These data indicate that cav-2 phosphoryla-
tion by IR tyrosine kinase is an upstream signal of the IR-catalyzed IRS-1
tyrosine phosphorylation. As the requirement of cav-2 tyrosine phos-
phorylation for its interaction with IRS-1 was investigated, insulin-
induced IRS-1 binding to Y19A, Y27A, or Y19A/27A mutant was de-
creased as compared to WT cav-2 (Fig. 2E). No interaction of cav-2
with Shc was further conﬁrmed (Fig. 2E). When IRS-1-binding region
of cav-2 was examined by in vitro binding assay, IRS-1 interacted with
Δ1-13, Δ47-86, and Δ120-162 but not with Δ1-46 and Δ1-70 mutants
(Fig. 2F), indicating that IRS-1 interacts with the N-terminal domain
(residues 14-46) of cav-2 which contains Tyr-19 and Tyr-27.
We then tested effects of cav-2 siRNA and tyrosine deﬁcient Y19/27A
mutant on insulin-induced IRS-1 associationwith and activationby IR in
3T3L1 adipocytes. Both cav-2 siRNA and Y19/27Amutant abrogated the
IRS-1 interaction with pY1162/1163-IR and tyrosine phosphorylation
(Fig. 3A, a, lanes 2 vs. 4 and Fig. 3B, a, lanes 4 vs. 6) and reduced the
downstream activation of Akt and ERK as compared to their scramble
control (Fig. 3A, b, lanes 2 vs. 4) and WT cav-2-transfected adipocytes
(Fig. 3B, b, lanes 4 vs. 6). Finally, we generated a phosphomimetic cav-
2 tyrosine mutant, Y19/27E to verify insulin- and/or cav-2 tyrosine
phosphorylation-dependent interaction between IR and cav-2 and
IRS-1 and enhancement of IRS-1 tyrosine phosphorylation and down-
stream signaling activation. Like WT cav-2, tyrosine phosphorylation
of the IRS-1 interacting with Y19/27E mutant by IR tyrosine kinase
and the consequent IRS-1-directed activation of Akt and ERK were
Fig. 2.Cav-2 knockdownand tyrosine deﬁcientmutation attenuate the IRS-1 interactionwith IR tyrosine kinase to activate IRS-1-directed PI3K-Akt and ERK signaling. (A-C)Vector control
or cav-2 shRNA stable Hirc-B cells (A, B) and scramble control or IRS-1 siRNA-transfected Hirc-B cells (C) were treated with or without 100 nM insulin for 10 min. WCL were
immunoprecipitated with anti-IRS-1(A, a), anti-p85α (A, b), anti-Shc (B), or anti-IR (C, b) antibody and/or subjected to immunoblot analysis with antibodies against IR, pY1162/1163-
IR, cav-2, pY19-cav-2, PY20, IRS-1, p85α, Shc, pS473-Akt, Akt, pT202/204-ERK, ERK, cav-1, and actin (A, c and C, a). The densitometry ratios of p-p85α to total p85α, p-IR to total IR,
p-Akt to total Akt, p-ERK to total ERK, cav-2 to actin, and IRS-1 to actin are illustrated (mean ± S.E., n= 3). NS, nonsigniﬁcant. (D) HEK293T cells were transfected with FLAG vector,
FLAG-cav-2, or FLAG-Y19/27A followedby incubationwith orwithout 100 nM insulin for 10min.WCLwere immunoprecipitatedwith anti-IR antibody and subjected to immunoblot anal-
ysis with antibodies against IRS-1, FLAG, pY1162/1163-IR, and IR. (E) HEK293T cells were transfectedwith FLAG-cav-2, FLAG-Y19A, FLAG-Y27A, or FLAG-Y19/27A followed by incubation
with or without 100 nM insulin for 10 min. WCL were immunoprecipitated with anti-FLAG antibody and subjected to immunoblot analysis with antibodies against IRS-1, Shc, and FLAG.
(F) HEK293T cells were treated with 100 nM insulin for 10 min and WCL were subjected to in vitro binding assay using puriﬁed MBP vector, MBP-cav-2, MBP-Δ1-13, MBP-Δ1-46, MBP-
Δ1-70, MBP-Δ47-86, or MBP-Δ120-162.
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8). These results show that insulin-activated IR tyrosine kinase-
catalyzed phospho-Tyr-19 and Tyr-27 cav-2 facilitates IRS-1 recruit-
ment to and association with IR, thereby mediating tyrosine phosphor-
ylation of IRS-1 by IR for the downstream IR signaling activation of the
IRS-1-directed both PI3K-Akt and ERK pathways.3.4. Cav-2 is myristoylated at Gly-2 and palmitoylated at Cys-109, Cys-122
and Cys-145
The C-terminal domain of cav-2 important for its IR binding has
cysteine residues for putative palmitoylation. Cys-109, Cys-122, and
Cys-145 are predicted by CSS-Palm, a palmitoylation prediction
Fig. 3. Insulin-activated IR-catalyzedphosphorylation of cav-2 at Tyr-19 and Tyr-27 facilitates IRS-1 recruitment to and tyrosine phosphorylation by IR for downstream signaling activation.
Scramble control or cav-2 siRNA (A) and FLAG vector, FLAG-cav-2, FLAG-Y19/27A, or FLAG-Y19/27E-transfected (B) 3T3L1 adipocytes were treated with or without 100 nM insulin for
10 min. WCL were immunoprecipitated with anti-IRS-1 (A and B, a) antibody and/or subjected to immunoblot analysis with antibodies against IR, pY1162/1163-IR, cav-2, pY19-cav-2,
PY20, IRS-1, FLAG, pS473-Akt, Akt, pT202/204-ERK, ERK, cav-1, and actin (A and B, b). Ecto, ectopic; Endo, endogenous. The densitometry ratios of p-IR to total IR, p-Akt to total Akt, p-
ERK to total ERK, and cav-2 to actin are illustrated (mean ± S.E., n= 3).
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Cys-145 are palmitoylated, we performed 3H-palmitate incorporation
and FAE assays with variant cysteine deﬁcient mutants. Both endoge-
nous and ectopic cav-2 were metabolically palmitoylated (Fig. 4B, a
and b) but mutation of all three cysteine residues to alanines (3CA)
abolished 3H-palmitate incorporation (Fig. 4B, b). Palmitoylation of
cav-2, along with cav-1 as a positive control [21], was further demon-
strated by FAE assay in Rat-1 ﬁbroblasts (Fig. 4B, c). Palmitoylation of
double cysteine deﬁcient mutants (C109/122A, C122/145A, and C109/
145A) was attenuated, and 3CA palmitoylation was completely
abolished (Fig. 4B, d). To explore dynamics of cav-2 palmitoylation,
effect of 2-BP, a nonmetabolizable analog of palmitate acting as an
irreversible inhibitor of palmitoylation, treatment for various time
points on the status of endogenous cav-2 palmitoylation was analyzed
in CHX-treated Hirc-B cells (Fig. 4C). There was no signiﬁcant cav-2
palmitoylation turnover observed until 1 h exposure to 2-BP.
The irreversible inhibition of cav-2 palmitoylation by 2-BP was started
after 1 h exposurewith 1.6-3.5 fold reduction in the level of endogenouscav-2 palmitoylation within 3-6 h exposure, suggesting that
depalmitoylation of the preexisting palmitoylated cav-2 and
repalmitoylation of the depalmitoylated cav-2 take place within the
time frame (Fig. 4C, a). The inhibition by 2-BP was completed at 12 h
exposure. We then explored if insulin induces cav-2 palmitoylation in
the cells which were pretreated with CHX and 2-BP to inhibit de novo
synthesis and palmitoylation of cav-2 and chased in serum-free or
insulin containing medium for various periods of time (Fig. 4C, b).
Palmitoylation of preexisting endogenous cav-2 was completely
blocked after the pretreatment with CHX and 2-BP (at 0 time chase)
and the inhibition status of cav-2 palmitoylation was not changed in
serum-free medium at all the chasing time. However, insulin triggered
palmitoylation of newly synthesized cav-2 as early as 15 min of insulin
incubation, and insulin-induced cav-2 palmitoylation was maintained
for 12 h. Distinct from cav-1 and cav-3, cav-2 displays a putative
myristoylation site at Gly-2 in the N-terminus (Fig. 4A). To verify if
cav-2 is myristoylated, Gly-2 was substituted by alanine (G2A) and
metabolic labeling with 3H-myristate was performed. WT cav-2 was
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palmitoylated (Fig. 4D, a and b). These results show that cav-2 is
myristoylated at Gly-2 and the myristoylation is a prerequisite for its
palmitoylation.
3.5. Intracellular localization of cav-2 depends on its fatty acylation status
Having demonstrated that cav-2 localizes in the ER, Golgi and PM,
and translocates from the Golgi to the PM [15,16], we sought to deter-
mine whether the subcellular distribution and intracellular transloca-
tion of cav-2 are dependent upon its different fatty acylation status. As
demonstrated [15,16], cav-2 localized in the Golgi and the PM, and
cav-2 colocalized with IR in the PM (Fig. 5A, panels 1 and 2). However,
G2A, 3CA, and C122/145A mutants were retained in the ER (Fig. 5A,
panels 3-5). Both C109/145A and C109/122Amutants remainedmainly
in theGolgi and exhibited no PM targeting (Fig. 5A, panels 6 and 7). Line
proﬁle analysis veriﬁed the colocalization with the appropriate subcel-
lular localization markers. Inhibition of the PM targeting of the mutants
was further conﬁrmed with the puriﬁed PM fraction (Fig. 5B). These re-
sults show that myristoylation at Gly-2 and palmitoylation at Cys-122
or Cys-145 are important for cav-2 translocation from the ER to the
Golgi, and that cav-2 myristoylation and palmitoylation at both Cys-
122 and Cys-145 are required for transport of cav-2 from the Golgi to
the PM for its colocalization with IR.
3.6. Fatty acylation is required for cav-2 function as a substrate for IR
tyrosine kinase and IR-cav-2-IRS-1-directed activation of mitogenic
and metabolic insulin signaling
We next explored requirement of cav-2 fatty acylation for its cataly-
sis by IR, IRS-1 interaction with IR, and IRS-1-directed activation of Akt
and ERK. G2A or 3CA mutant-expressed cells exhibited retardation of
IR-catalyzed phosphorylation at Tyr-19 (Fig. 6A, a, lanes 4 vs. 6 and 8),
abrogation of the interaction between IR and IRS-1 (Fig. 6A, b), and in-
hibition of the IRS-1-directed downstream signaling activation of Akt
and ERK (Fig. 6A, a, lanes 4 vs. 6 and 8). These results show that cav-2
myristoylation and palmitoylation facilitate its binding to IR and the
subsequent phosphorylation catalyzed by IR tyrosine kinase to mediate
the IRS-1 association with and activation by IR, thereby activating the
IRS-1-directed downstream signaling. To signify functional and physio-
logical relevance of cav-2 fatty acylation, 3T3L1 adipocytes were tested
for the effect of cav-2 palmitoylation on phospho-tyrosine cav-2-
mediated IR-IRS-1-directed signaling activation. Ectopically introduced
WT cav-2, but not 3CA mutant, was phosphorylated at Tyr-19 (Fig. 6B,
a, lanes 4 vs. 6), facilitated association between IR and pY19-cav-2 and
IRS-1 (Fig. 6B, b, lanes 4 vs. 6), and enhanced downstream activation
of Akt and ERK (Fig. 6B, a, lanes 4 vs. 6) in response to insulin. Ectopic
expression of bothWT cav-2 and 3CAmutant did not affect endogenous
cav-1 level (Fig. 6B, a).
Caveolae-dependent IR signaling is well characterized in 3T3L1
adipocytes [38]. To distinguish the cav-2 speciﬁc activation in IR
signaling from the caveolae- and cav-1-mediated regulation, 3T3L1
preadipocytes and adipocytes were pretreated with MβCD to deplete
cholesterol from the PM or subjected to cav-1 depletion before insulin
stimulation. We then asked if blocking cav-2 palmitoylation has impact
on cell proliferation in the preadipocytes and on cell survival andFig. 4. Fatty acylation of cav-2. (A) Schematic illustration of cav-2 showing the a.a. sequences of
predicted for the myristoylation and palmitoylation of cav-2. (B) Hirc-B (a) and FLAG-cav-2 or
palmitate. WCL were immunoprecipitated with anti-cav-2 (a) or anti-FLAG (b) antibody an
FLAG. Rat-1 (c) and FLAG-cav-2, FLAG-C109/122A, FLAG-C122/145A, FLAG-C109/145A, or FLA
hydroxylamine (HA) or Tris as a control. Input shows starting material before the NeutrAvidi
by incubation with DMSO or 100 μM 2-BP for the indicated time periods and subjected to FA
⁎⁎p b 0.01, ⁎⁎⁎p b 0.001. (b) Hirc-B cells were treated with 100 μM 2-BP and 50 μM CHX for
nM insulin containing medium (insulin) and subjected to FAE analysis. The densitometry ra
G2A-GFP-transfectedHEK293T cells were subjected tometabolic labeling using 3H-myristate (a
ed to autoradiography or immunoblot analysis with antibody against GFP. The asterisk represeglucose uptake in the adipocytes. Ectopic introduction of WT cav-2 in-
creased insulin-induced preadipocyte proliferation by 29.1% as com-
pared to vector control (Fig. 6C, a, lanes 1 vs. 2), but 3CA mutant had
no effect (Fig. 6C, a, lanes 1 vs. 3). No signiﬁcant change was observed
in the adipocyte viability when WT cav-2 was introduced (Fig. 6C, b,
lanes 1 vs. 2), but 3CA mutant decreased the viability by 61.5% as
compared to vector control (Fig. 6C, b, lanes 1 vs. 3). The patterns of
cav-2-mediated increase in the preadipocyte proliferation and cav-2
palmitoylation defect-induced decrease in the adipocytes viability
were not affected from cholesterol depletion by MβCD treatment
(Fig. 6C, a and b, lanes 1-3 vs. 4-6). These results show that cav-2 inde-
pendently of caveolae regulates insulin-induced cell survival and prolif-
eration via the palmitoylated cav-2-mediated IR-IRS-1-directed PI3K-
Akt- and ERK-dependent signaling. Insulin-stimulated glucose uptake
measured by using 2-NBDG showed increased 2-NBDG uptake by 4.6
and 4.7 fold in non- and vector-transfected control adipocytes not treat-
ed with MβCD, respectively (Fig. 6C, c, lanes 1 vs. 5 and 2 vs. 6). Ectopic
WT cav-2, but not 3CAmutant, enhanced the uptake by 2.0 fold as com-
pared to the uptake level of the control adipocytes (Fig. 6C, c, lanes 6 vs.
7 vs. 8). Similar uptake patternswere observed in the control adipocytes
transfectedwith scramble control (Fig. 6D, a, lanes 1 vs. 5 and 2 vs. 6 and
lanes 6 vs. 7 vs. 8). Cholesterol depletion and cav-1 knockdown reduced
insulin-induced 2-NBDG uptake by 2.8 and 2.9 fold, respectively in con-
trol adipocytes (Fig. 6C, c and D, a, 6 vs. 14). Ectopic WT cav-2 rescued
the reduction to the uptake level of control adipocytes but not 3CAmu-
tant (Fig. 6C, c and D, a, lanes 14 vs. 15 vs. 16 and 6 vs. 15), demonstrat-
ing the palmitoylated cav-2-speciﬁc and caveolae/cav-1-independent
glucose uptake. Cholesterol and cav-1 levels were depleted by 70.6
and 91% in MβCD-treated and cav-1 siRNA-transfected adipocytes, re-
spectively (Fig. 6C, d and D, b). These results provide further evidence
that fatty acylated cav-2 activates insulin signaling distinct from which
regulated by cav-1 and caveolae.
4. Discussion
In this study, we demonstrate that cav-2 is a substrate of IR tyrosine
kinase to facilitate insulin signaling.We propose amodel for the regula-
tory mechanisms of cav-2 in insulin signaling (Fig. 7). Under basal con-
dition, co-translationally myristoylated cav-2 at Gly-2 is synthesized in
the ER. Upon insulin stimulation, myristoylated cav-2 is palmitoylated
at Cys-109, Cys-122, and Cys-145 in the ER. Myristoylation of cav-2 is
a prerequisite for its subsequent palmitoylation. Fatty acylated cav-2
is transported to the PM via Golgi. The PM targeted cav-2 forms
homooligomeric cav-2 noncaveolar microdomain in the PM, where
cav-2 facilitates IR recruiting and regulates activation of insulin signal-
ing cascade by direct interaction with IR [16]. The C-terminal domain
of fatty acylated cav-2 associates with the NPEY motif of insulin-
activated IR in the noncaveolar microdomain and insulin-activated IR
tyrosine kinase catalyzes Tyr-19 and Tyr-27 phosphorylation of cav-2.
The phospho-Tyr-19 and Tyr-27 cav-2 facilitates IRS-1 recruitment to
and association with IR, thereby mediating tyrosine phosphorylation
of IRS-1 by IR for IRS-1-directedmetabolic andmitogenic insulin signal-
ing activation.
Many signaling proteins are proposed to use conserved caveolin-
binding motifs (CBMs) to associate with caveolae via the caveolin scaf-
folding domain (CSD) [39]. It has been reported that the scaffoldingN-terminal residues 1-27 and C-terminal residues 100-162. Asterisks indicate a.a. residues
FLAG-3CA-transfected HEK293T (b) cells were subjected to metabolic labeling using 3H-
d subjected to autoradiography or immunoblot analysis with antibody against cav-2 or
G-3CA-transfected HEK293T (d) cells were subjected to FAE analysis after treatment with
n afﬁnity puriﬁcation. (C) (a) Hirc-B cells were treated with 50 μM CHX for 3 h followed
E analysis. The densitometry ratios of FAE to Input are illustrated (mean ± S.E., n = 3).
15 h, rinsed, and chased for the indicated times in serum-free medium (control) or 100
tios of FAE to Input are illustrated (mean ± S.E., n = 3). ⁎⁎⁎p b 0.001. (D) Cav-2-GFP or
) or 3H-palmitate (b).WCLwere immunoprecipitatedwith anti-GFP antibody and subject-
nts nonspeciﬁc bands.
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Fig. 6. Fatty acylation of cav-2 is required for IR tyrosine kinase-catalyzed phosphorylation of cav-2 and IRS-1 and IR-cav-2-IRS-1-directed activation of mitogenic and metabolic insulin
signaling distinct from the caveolae/cav-1-dependent activation. (A, B) HEK293T cells (A) or 3T3L1 adipocytes (B) were transfected with FLAG vector, FLAG-cav-2, FLAG-G2A, or FLAG-
3CA followed by incubation with or without 100 nM insulin for 10 min. WCL were immunoprecipitated with anti-IR antibody (A and B, b) and/or subjected to immunoblot analysis
with antibodies against FLAG, IRS-1, pY1162/1163-IR, IR, pY19-cav-2, pS473-Akt, Akt, pT202/204-ERK, ERK, cav-2, cav-1, and actin (A and B, a). Ecto, ectopic; Endo, endogenous. The
densitometry ratios of pY19-cav-2 to FLAG, p-Akt to total Akt, and p-ERK to total ERK are illustrated (mean ± S.E., n= 3). The asterisks represent nonspeciﬁc bands. (C) FLAG vector,
FLAG-cav-2, or FLAG-3CA-transfected 3T3L1 preadipocytes (a) and adipocytes (b) were pretreated with or without 10 mMMβCD for 2 h followed by incubation with 100 nM insulin
for 72 h and subjected to cell proliferation and viability assay, respectively (mean± S.E., n=3). (c) FLAG vector, FLAG-cav-2, or FLAG-3CA-transfected 3T3L1 adipocytes were pretreated
with or without 10mMMβCD for 2 h followed by incubation with or without 100 nM insulin for 10min and subjected to glucose uptake assay (mean± S.E., n=3). NT, nontransfected.
(d) Cholesterol depletion by10mMMβCD treatment for 2 h in 3T3L1 preadipocytes and adipocyteswasmeasuredby a cholesterol assay kit (mean±S.E., n=3). (D) (a) 3T3L1 adipocytes
were co-transfected with scramble control or cav-1 siRNA and FLAG vector, FLAG-cav-2, or FLAG-3CA followed by incubation with or without 100 nM insulin for 10min and subjected to
glucose uptake assay (mean± S.E., n=3). NT, nontransfected. (b) Scramble control or cav-1 siRNA-transfected 3T3L1 adipocytes were subjected to immunoblot analysiswith antibodies
against cav-1 and actin. The densitometry ratios of cav-1 to actin are illustrated (mean ± S.E., n= 3).
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sine kinase domain of the IRβ-subunit [2,3], and that scaffolding domain
peptides derived from cav-1 and cav-3 increase tyrosine kinase activity
of the IR [3]. Recent structural and bioinformatic analyses, however,
have shown that the CSD located very close to themembrane has limit-
ed access to interact with the previously proposed proteins containing
the CBM [9,40], and that putative CBMs are buried and inaccessible to
the CSD [8,9]. Cav-2 differs from cav-1 and cav-3 in its interactionFig. 5. Intracellular localization of cav-2 is dependent on its fatty acylation status. (A) HEK293T c
GFP, or C109/122A-GFP and pECFP-Golgi or pECFP-ER, or cav-2-mCherry and IR-GFP and visual
verted to lineproﬁles using the Line Proﬁle Tool. (B)HEK293T cellswere transfectedwith FLAG-
PM isolation as described [15,16]. WCL and PM fraction were subjected to immunoblot analysis
and α-tubulin as markers for the PM fraction, ER and cytoplasm, respectively.with IR. As the present data show, cav-2 interacts with IR by binding
to the NPEY motif in the juxtamembrane domain of IR but not to the
cav-1 and cav-3 bindingmotif in the IR. IR associateswith cav-2 by bind-
ing to the C-terminal domain of cav-2, where Cys-109, Cys-122, and
Cys-145 are palmitoylated, but not to the cav-2 scaffolding domain.
The distinct cav-2 binding to the NPEY motif is essential for the IR tyro-
sine kinase-catalyzed phosphorylation of cav-2 at Tyr-19 and Tyr-27.
The present data also show that cav-2 recruits IRS-1 to IR through IRS-ells were co-transfectedwith cav-2-GFP, G2A-GFP, 3CA-GFP, C122/145A-GFP, C109/145A-
ized by confocal microscopy. Scale bars, 10 μm. Thewhite lines inmerge panels were con-
cav-2, FLAG-3CA, FLAG-C109/122A, FLAG-C122/145A, or FLAG-C109/145Aand subjected to
with antibody against FLAG and detectedwith antibodies speciﬁc for E-cadherin, calnexin
Fig. 7. Regulatory mechanisms of cav-2 in IR signaling. Upon insulin stimulation, newly synthesizedmyristoylated cav-2 is palmitoylated at Cys-109, Cys-122, and Cys-145 in the ER. The
fatty acylated cav-2 is transported to the PM through theGolgi. The PM-targeted fatty acylated cav-2 associateswithNPEYmotif of insulin-activated IR and is phosphorylated at Tyr-19 and
Tyr-27 by IR tyrosine kinase in the noncaveolarmicrodomain. The phospho-tyrosine cav-2 facilitates IRS-1 associationwith and tyrosine phosphorylation by IR for IRS-1-directed PI3K-Akt
and ERK activation responsible for glucose uptake and cell survival and proliferation.
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the IRS-1-directed downstream PI3K-Akt and ERK signaling activation.
Thus, our ﬁndings show that cav-2 acts as a scaffolding molecule facili-
tating IRS-1 associationwith IR and regulates the IR-cav-2-IRS-1-direct-
ed insulin signaling activation.
Cav-2 among caveolin gene family exhibits themost divergent geno-
mic structure and sequence homology. One of the distinctive features is
that cav-2 contains the myristoylation consensus site sequence (Met-
Gly) in the N-terminus [41]. The present data demonstrate for the ﬁrst
time that cav-2 is myristoylated at Gly-2, and that the myristoylation
is required for the subsequent palmitoylation of Cys-109, Cys-122, and
Cys-145. The fatty acylation is not only essential but also a precondition
for its tyrosine phosphorylation by IR to activate the IRS-1-directed
downstream insulin signaling. Given that cav-2 myristoylation is a
prerequisite for its palmitoylation and that the residues 120-162 in
the C-terminal domain are important to interact with IR, myristoylation
at Gly-2 and palmitoylation at Cys-122 and Cys-145 seem critical to fa-
cilitate its binding to IR and the subsequent tyrosine phosphorylation.
The present study, therefore, gives the ﬁrst assessment of a regulatory
function of cav-2 fatty acylation in IR signaling.
We have previously demonstrated that cav-2 formshomooligomeric
microdomain in the PM for initiation of insulin signaling via IR recruit-
ment, and that ectopic cav-2 rescues the defective IR signaling caused
bydepletion of caveolae and/or cav-1 down regulation by reconstituting
the homooligomeric cav-2 microdomain in the PM [16]. The present
data show that failure in the cav-2 fatty acylation results in prevention
of the PM targeting of cav-2 and its colocalization with IR in the PM.
Fatty acylated cav-2 enhances insulin-induced ERK and Akt activations
and regulates cell proliferation and viability. And WT cav-2, but not
the fatty acylation deﬁcient mutants, ameliorates the retardation of
insulin-stimulated glucose uptake in caveolae- or cav-1-depleted adipo-
cytes. The data and our previous ﬁndings, thus, suggest that cav-2 fatty
acylation is important for the formation of the homooligomeric cav-2
microdomain in the PM and the direct interaction of cav-2 with IR in
the microdomain for the IR-cav-2-IRS-1-directed insulin signaling acti-
vation, distinct from those of the IR-Shc-directed and the caveolae/
cav-1-dependent.Thepresent data demonstrate that fatty acylation at speciﬁc site is im-
portant for the intracellular localization of cav-2. G2A, 3CA, and C122/
145Amutants remain in the ERwhereas C109/145A and C109/122Amu-
tants translocate to and remain in the Golgi. All of themutants are unable
to localize in the PM. These data show that myristoylation at Gly-2 and
palmitoylation at Cys-122 or Cys-145 are important for cav-2 transloca-
tion from the ER to the Golgi. Cav-2 myristoylation and palmitoylation
at both Cys-122 and Cys-145 are required for its colocalization with IR
in the PM. Rab6, but not Rab5 and Rab1, interacts with cav-2 and regu-
lates vesicular transport of cav-2 [15,16]. It will be interesting to test if
fatty acylation status of cav-2 affects its association with the small
GTPases, thereby regulating intracellular vesicular trafﬁcking of cav-2.
Palmitoylation is catalyzed by palmitoyl acyltransferases, also known
as Asp-His-His-Cys (DHHC)-domain containing proteins. Mammalian
DHHC family consists of 23members and their speciﬁc subcellular local-
ization in the ER, Golgi, and PMwas reported [42,43]. Two cytosolic acyl
thioesterases (APT1 and APT2) have been identiﬁed as palmitoyl
thioesterases [44,45] but the APTs that control depalmitoylation of solu-
ble andmembraneproteinswere not deﬁned. Given that the 3CAmutant
is retained in the ER and that insulin triggers palmitoylation of newly
synthesized cav-2, the present data indicate that the palmitoylation of
newly synthesized cav-2 in the ER is catalyzed withinmin by the ER res-
ident insulin-speciﬁc DHHC and suggest the existence of a novel insulin
signaling, regulating palmitoylation of cav-2 in the ER. Having shown
that palmitoylated cav-2 is transported to the PM and acts as a substrate
for IR tyrosine kinase and that palmitoylated cav-2 undergoes its
turnover of depalmitoylation and repalmitoylation within hours, the
present data suggest that the turnover of cav-2 are processed by the
APT and DHHC in the PM. Further studies are needed to identify the
enzymes responsible for and address the regulatory mechanisms
controlling palmitoylation and depalmitoylation of cav-2 by speciﬁc
DHHC and APT, respectively, which localize in a particular intracellular
compartment.
Cav-2 is widely present and its expression is up-regulated in various
tumor cells [46–49]. Micro-ribonucleic acid 199a-3p-targeted cav-2
regulates proliferation and survival of tumor cells [50]. Nevertheless,
the functional role of cav-2 is not well-deﬁned in tumor growth and
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sion has not been fully investigated. Expression level of cav-2 is changed
after high-fat feeding in rat white adipose tissue and skeletal muscle
[51–53]. A common single nucleotide polymorphism located in the
cav-2 gene (rs2270188) associates with dietary fat to affect risk of
type 2 diabetes [54]. Micro-ribonucleic acid 29 (miR-29), which regu-
lates Akt-mediated glucose uptake in adipocytes, is up-regulated in
skeletal muscles of type 2 diabetic Goto-Kakizaki rats. Cav-2 is found
to be one of the target genes of the miR-29, and cav-2 expression is sig-
niﬁcantly decreased in skeletal muscle and liver tissue of the diabetic
rats [55]. Although these results indicate that cav-2 as a candidate
gene involved in the nutritional disorder and insulin resistance related
to many metabolic alterations, how cav-2 modulates insulin signaling
activation in the metabolic alternations has not been explored.
Our present ﬁndings provide the molecular mechanisms through
which cav-2 manifests insulin signaling activation of the IR-cav-2-IRS-
1-directed metabolic and mitogenic pathways, and demonstrate the
regulatory functions of cav-2 controlled by its expression, fatty acyla-
tion, oligomerization, and phosphorylation.
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